scholarly journals PERAN VISUAL EVOKED POTENTIAL PADA PASIEN DIABETES MELITUS TIPE-2 DENGAN DAN TANPA RETINOPATI DIABETIK

2018 ◽  
Vol 35 (3) ◽  
Author(s):  
Bill Jones Tanawal ◽  
Melke Joanne Tumboimbela ◽  
Corry Novita Mahama
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetic Retinopathy ◽  
Visual Evoked Potential ◽  
Evoked Potential ◽  
P100 Latency ◽  
Diabetes Melitus ◽  
Visual Evoked

ROLE OF VISUAL EVOKED POTENTIAL IN TYPE-2 DIABETES MELLITUS WITH AND WITHOUT DIABETIC RETINOPATHYABSTRACTIntroduction: Diabetic retinopathy (DR) is a common complication of type-2 diabetes mellitus (T2DM). Minimal functional change of neural layers of the retina occurs before structural changes, thus undetected by funduscopy. This damage could be identified earlier by P100 latency changes in visual evoked potential (VEP).Aims: To find the characteristic  of P100 in T2DM with and without DR, its correlation  with the duration of thedisease and the level of fasting blood glucose (FBG).Methods: A cross sectional analysis study was conducted in Prof. dr. R.D. Kandou Hospital, Manado, from November2017-January 2018. T2DM patients aged 18-60 with visual acuity  >6/60, without neuro-ophtalmological disorders and other metabolic diseases. P100 latency was measured using VEP with reversed checkerboard stimulation.Results: There were 56 subjects with T2DM, mostly were females (57,1%) and age mean was 54,86±5,65 years. Delayed P100 latency occurred in 85,7% subjects. Diabetic retinopathy subjects showed delayed P100 latency on right (92,31%) and left (88%) eyes while T2DM subjects without retinopathy showed delayed P100 latency on both eyes 70%. There were strong and significant positive correlation between the duration of T2DM and P100 latency on the right and left eyes. There was no significant correlation between fasting blood glucose (FBG) level and P100 latency.Discussions: Delayed P100 latency occurs in T2DM patients with and without retinopathy. The duration of T2DMcorrelates with the delay of P100 latency but not with the level of FBG.Keywords: Diabetic retinopathy, P100, type-2 diabetes mellitus, visual evoked potential ABSTRAKPendahuluan: Retinopati diabetik adalah suatu komplikasi yang umum terjadi pada diabetes melitus tipe-2 (DMT2). Sebelum terjadinya perubahan struktural, lapisan neuron retina pasien DMT2 sudah mengalami perubahan fungsional minimal yang tidak terdeteksi dengan funduskopi. Hal ini dapat diidentifikasi lebih dini berdasarkan gambaran latensi gelombang P100 pada pemeriksaan visual evoked potential (VEP).Tujuan: Untuk mengetahui karakteristik nilai gelombang P100 pada pasien DMT2 dengan dan tanpa retinopati diabetik, serta hubungannya dengan lama penyakit dan kadar glukosa darah puasa (GDP).Metode: Penelitian analitik dengan desain potong lintang terhadap pasien DMT2 yang dirawat di RSUP Prof. dr. R.D. Kandou, Manado periode November 2017-Januari 2018. Subjek berusia 18-60 tahun dengan visus >6/60 tanpa adanya kelainan neuro-oftamologi dan penyakit metabolik lain. Dilakukan perekaman VEP menggunakan stimulasi reversed checkerboard dilanjutkan pengukuran latensi gelombang P100.Hasil: Didapatkan 56 subjek, paling banyak perempuan (57,1%) dan rerata usia 54,86±5,65 tahun. Latensi P100 memanjang pada 85,7% subjek. Pada subjek dengan retinopati ditemukan mayoritas mengalami pemanjangan latensi pada mata kanan (92,31%) dan mata kiri (88%), sedangkan pada subjek tanpa retinopati ditemukan pemanjangan latensi kedua mata adalah 70%. Terdapat hubungan bermakna dengan korelasi positif kuat antara lamanya DMT2 dan latensi P100 kanan dan kiri. Tidak terdapat hubungan yang bermakna antara kadar GDP dan latensi P100.Diskusi: Pemanjangan latensi P100 terjadi pada subjek DMT2 dengan dan tanpa retinopati. Lamanya DMT2 berhubungan dengan pemanjangan latensi P100, tetapi kadar GDP tidak berhubungan dengan pemanjangan latensi P100.Kata kunci: Diabetes melitus tipe-2, P100, retinopati diabetik, visual evoked potential

scholarly journals Mikroenkapsulasi Kombinasi Curcumin pada Kunyit (Curcuma Longa) dan Epigallocatechin-3-Gallate (EGCG) pada Daun Teh Hijau (Camellia Sinensis): Inovasi Terapi Pencegahan Diabetik Retinopati pada Penderita Diabetes Melitus Tipe 2

2020 ◽  
Vol 1 (2) ◽  
pp. 11
Author(s):  
Hans Andre Hamonangan Simorangkir
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetic Retinopathy ◽  
Preventative Therapy ◽  
Tea Leaves ◽  
Green Tea Leaves ◽  
Dm Type 2 ◽  
Diabetes Melitus

ABSTRAK Retinopati diabetik adalah komplikasi mikrovaskular diabetes mellitus tipe 2 (DM Tipe 2) yang menjadi penyebab utama kebutaan pada orang dewasa. Penderita DM Tipe 2 berisiko 25 kali lebih mudah mengalami kebutaan dibanding nondiabetes. Minimnya pengetahuan pasien mengenai gejala, tidak adekuatnya pelayan kesehatan, dan masalah ekonomi merupakan faktor yang menyebabkan sulitnya penanganan retinopati diabetik. Kombinasi curcumin pada kunyit dan epigallocatechin-3-gallate (EGCC) pada daun teh hijau memiliki keunggulan sebagai terapi pencegahan diabetik retinopati. Curcumin adalah komponen utama kunyit, senyawa polifenol golongan flavonoid ini memiliki beragam khasiat sebagai antiinflamasi, antioxidant, antiangiogenik, dan antiproliferatif. EGCG merupakan komponen paling aktif yang ditemukan pada teh hijau dan memiliki efek antioxidant paling kuat. Senyawa aktif yang ada pada kedua tumbuhan tersebut memilki efek yang spesifik dalam mencegah terjadinya diabetik retinopati. Beberapa mekanisme berlangsung dalam tingkat sel sehingga efek yang diperoleh lebih efisien. Senyawa aktif curcumin dan EGCG merupakan senyawa alami yang berasal dari tanaman sehingga tidak akan menimbulkan efek samping pada dosis normal. Penggunaan metode mikroenkapsulasi dalam mengemas ekstak kunyit dan daun teh hijau akan membantu efektivitas kerja masing –masing zat aktif yang terkandung di dalam kedua tumbuhan tersebut. Zat aktif tersebut nantinya akan dikemas dalam bentuk butiran kecil yang penggunaannya dapat dikonsumsi langsung oleh penderita diabetes melitus tipe 2 sebagai terapi pencegahan diabetik retinopati. Kata Kunci: Curcumin, DM Tipe 2, EGCC, Mikroenkapsulasi, Retinopati Diabetik   ABSTRACT Diabetic retinopathy is a microvascular complication of type 2 diabetes mellitus (DM type 2) which is a major cause of blindness in adults. Patients with Type 2 diabetes are 25 times more likely to replace blindness than non-diabetics. The lack of patient knowledge about the symptom, inadequate health services, and economic problems are factors that cause difficulties in handling diabetic retinopathy. The combination of curcumin in turmeric and epigallocatechin-3-gallate (EGCC) on green tea leaves has an advantage as a preventative therapy for diabetic retinopathy. Curcumin is the main component of turmeric, the polyphenol compound of the flavonoid group has a variety of properties as anti-inflammatory, antioxidant, antiangiogenic, and antiproliferative. EGCG is the most active component found in green tea leaves and has the strongest antioxidant effect. The active compounds in both plants have specific effects on the use of diabetic retinopathy. Some of the ongoing results at the cellular level produced are obtained more efficiently. The active compound curcumin and EGCG are natural compositions needed from plants so that they will not cause side effects at normal doses. The use of microencapsulation method in packaging turmeric extract and green leaves will help each of them - support the active substances contained in both plants. This active substance will be packaged in small granules that can be used directly by people with type 2 diabetes mellitus as a preventative therapy for diabetic retinopathy. Keywords: Curcumin, Diabetic Retinopathy, DM Type 2, EGCC, Microencapsulation.

scholarly journals Pattern-Reversal Visual Evoked Potentials Tests in Persons with Type 2 Diabetes Mellitus with and without Diabetic Retinopathy

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Raghda S. Al-Najjar ◽  
Nehaya M. Al-Aubody ◽  
Salah Z. Al-Asadi ◽  
Majid Alabbood
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetic Retinopathy ◽  
Visual Evoked Potentials ◽  
Pattern Reversal ◽  
Test Results ◽  
P100 Latency ◽  
Clinical Changes

Background. Currently, diabetic retinopathy (DR) has a wide recognition as a neurovascular rather than a microvascular diabetic complication with an increasing need for enhanced detection approaches. Pattern-reversal visual evoked potentials (PRVEPs) test, as an objective electrophysiological measure of the optic nerve and retinal function, can be of great value in the detection of diabetic retinal changes. Objectives. The use of two sizes of checkerboard PRVEPs testing to detect any neurological changes in persons with type 2 diabetes mellitus (T2DM) with and without a clinically detected DR. Also, to compare the results according to the candidate age, duration, and glycemic status of T2DM. Methods. This study included 50 candidates as group A with T2DM and did not have a clinically detected DR and 50 candidates as group B with T2DM and had a clinically detected early DR and 50 candidates as controls who were neither diabetic nor had any other medical or ophthalmic condition that might affect PRVEPs test results. The PRVEPs were recorded in the consultant unit of ophthalmology in Almawani Teaching Hospital. Monocular PRVEPs testing of both eyes was done by using large (60 min) and small (15 min) checks to measure N75 latency and P100 latency and amplitude. Results. There was a statistically significant P100 latency delay and P100 amplitude reduction in both groups A and B in comparison with the controls. The difference between groups A and B was also significant. In both test results of groups A and B, the proportions of abnormal P100 latency were higher than those of P100 amplitude with a higher abnormal proportions in 15 min test. Conclusions. The PRVEP test detected neurological changes, mainly as conductive alterations affecting mostly the foveal region prior to any overt DR clinical changes, and these alterations were heightened by the presence of DR clinical changes.

Angiopoietin 1 in patients with type 2 diabetes mellitus and diabetic retinopathy

2015 ◽  
Author(s):  
Sattar El-Deeb Abd El ◽  
Mohamed Halawa ◽  
Ahmed Saad ◽  
Inas Sabry ◽  
Maram Mahdy ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetic Retinopathy ◽  
Angiopoietin 1

Relationship between diabetic retinopathy and cerebral perfusion in type 2 diabetes mellitus

2018 ◽  
Vol 71 (1) ◽  
pp. 49-53
Author(s):  
N. Zherdiova ◽  
◽  
N. Medvedovska ◽  
B Mankovsky ◽  
◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetic Retinopathy ◽  
Cerebral Perfusion

Predicting the risk of diabetic retinopathy-associated macular edema in patients with type 2 diabetes mellitus

2019 ◽  
Vol 80 (3) ◽  
pp. 3-8
Author(s):  
S. Mogilevskyy ◽  
◽  
Iu. Panchenko ◽  
S. Ziablitsev ◽  
◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetic Retinopathy ◽  
Macular Edema

scholarly journals Metabolomics-based multidimensional network biomarkers for diabetic retinopathy identification in patients with type 2 diabetes mellitus

2021 ◽  
Vol 9 (1) ◽  
pp. e001443
Author(s):  
Jingjing Zuo ◽  
Yuan Lan ◽  
Honglin Hu ◽  
Xiangqing Hou ◽  
Jushuang Li ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetic Retinopathy ◽  
Permutation Test ◽  
Linear Regression Models ◽  
Characteristic Analysis ◽  
Network Biomarkers ◽  
Validation Set

IntroductionDespite advances in diabetic retinopathy (DR) medications, early identification is vitally important for DR administration and remains a major challenge. This study aims to develop a novel system of multidimensional network biomarkers (MDNBs) based on a widely targeted metabolomics approach to detect DR among patients with type 2 diabetes mellitus (T2DM) efficiently.Research design and methodsIn this propensity score matching-based case-control study, we used ultra-performance liquid chromatography-electrospray ionization-tandem mass spectrometry system for serum metabolites assessment of 69 pairs of patients with T2DM with DR (cases) and without DR (controls). Comprehensive analysis, including principal component analysis, orthogonal partial least squares discriminant analysis, generalized linear regression models and a 1000-times permutation test on metabolomics characteristics were conducted to detect candidate MDNBs depending on the discovery set. Receiver operating characteristic analysis was applied for the validation of capability and feasibility of MDNBs based on a separate validation set.ResultsWe detected 613 features (318 in positive and 295 in negative ESI modes) in which 63 metabolites were highly relevant to the presence of DR. A panel of MDNBs containing linoleic acid, nicotinuric acid, ornithine and phenylacetylglutamine was determined based on the discovery set. Depending on the separate validation set, the area under the curve (95% CI), sensitivity and specificity of this MDNBs system were 0.92 (0.84 to 1.0), 96% and 78%, respectively.ConclusionsThis study demonstrates that metabolomics-based MDNBs are associated with the presence of DR and capable of distinguishing DR from T2DM efficiently. Our data also provide new insights into the mechanisms of DR and the potential value for new treatment targets development. Additional studies are needed to confirm our findings.

Sign in / Sign up

Export Citation Format

Share Document